Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

This summary is generated by an algorithm. If you find any mistakes, let us know.

NEX raises $25M, launches Active Arcade to get people moving
NEX raises $25M, launches Active Arcade to get people moving
UN

Unicorn Nest news

NEX raises $25M, launches Active Arcade to get people moving

– NEX, a motion entertainment startup, raised $25m funding.
– The round was led by Blue Pool Capital and joined by Samsung Ventures, SparkLabs and Susquehanna.
– It brings NEX to a valuation of $100m.
– The company is building motion entertainment – content that encourages physical movement.

Source
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
UN

Unicorn Nest news

FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform

– FogPharma announced the completion of a $107m Series C financing round.
– The round was led by venBio Partners with participation from new investors Cormorant Asset Management, Farallon Capital Management, Invus, funds and accounts advised by T. Rowe Price Associates, Inc.; HBM Healthcare Investments, Casdin Capital, and PagsGroup.
– Existing investors, including GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital also participated in the oversubscribed round.
– FogPharma’s proprietary hyperstabilized α-helical peptides (Helicon™ peptides) are a new class of therapeutics that combine the targeting strength and specificity of antibodies with the broad tissue distribution, intracellular target engagement and oral dosing optionality of small molecules.

Source
1 2 3 58 59 60
Crunchbase icon

Content report

The following text will be sent to our editors: